-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Shi Bei
On October 20, Moderna registered the efficacy, safety and immunogen of its cytomegalovirus (CMV) mRNA vaccine mRNA-1647 in 16-40 year old female healthy subjects on the US clinical trial website (ClinicalTrials.
The study plans to recruit 6900 subjects.
The mRNA-1647 developed by Moderna contains 6 mRNA sequences, including 5 mRNA encoding the pentamer complex and 1 mRNA encoding the gB antigen
Unlike protein-based vaccines, mRNA-1647 refers to the production and production of functional antigens by the body's own cells, which mimic the antigens presented by CMV to the immune system during natural infection
Cytomegalovirus (CMV) is a common pathogen that belongs to the herpes virus family
CMV infection is common in young children who have never been exposed to the virus, and is acquired and spread through contact with saliva, breast milk, mucus, and urine